Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Myeloid folliculin balances mTOR activation to maintain innate immunity homeostasis
Jia Li, Shogo Wada, Lehn K. Weaver, Chhanda Biswas, Edward M. Behrens, Zoltan Arany
Jia Li, Shogo Wada, Lehn K. Weaver, Chhanda Biswas, Edward M. Behrens, Zoltan Arany
View: Text | PDF
Research Article Cell biology Immunology

Myeloid folliculin balances mTOR activation to maintain innate immunity homeostasis

  • Text
  • PDF
Abstract

The mTOR pathway is central to most cells. How mTOR is activated in macrophages and how it modulates macrophage physiology remain poorly understood. The tumor suppressor folliculin (FLCN) is a GAP for RagC/D, a regulator of mTOR. We show here that LPS potently suppresses FLCN in macrophages, allowing nuclear translocation of the transcription factor TFE3, leading to lysosome biogenesis, cytokine production, and hypersensitivity to inflammatory signals. Nuclear TFE3 additionally activates a transcriptional RagD-positive feedback loop that stimulates FLCN-independent canonical mTOR signaling to S6K and increases cellular proliferation. LPS thus simultaneously suppresses the TFE3 arm and activates the S6K arm of mTOR. In vivo, mice lacking myeloid FLCN reveal chronic macrophage activation, leading to profound histiocytic infiltration and tissue disruption, with hallmarks of human histiocytic syndromes, such as Erdheim-Chester disease. Our data thus identify a critical FLCN-mTOR-TFE3 axis in myeloid cells, modulated by LPS, that balances mTOR activation and curbs innate immune responses.

Authors

Jia Li, Shogo Wada, Lehn K. Weaver, Chhanda Biswas, Edward M. Behrens, Zoltan Arany

×

Figure 3

TFE3 promotes canonical mTORC1 activity through a transcriptional RagD feedback loop.

Options: View larger image (or click on image) Download as PowerPoint
TFE3 promotes canonical mTORC1 activity through a transcriptional RagD f...
(A) Western blot of BMDMs isolated from FLCNlox/lox (WT), FLCNlox/lox Lyz2 Cre (FLCN KO [KO]), and FLCNlox/lox Lyz2 Cre TFE3 KO (FLCN and TFE3 double-KO [DKO]) mice exposed to vehicle, CpG (10 μg/ml), or LPS (100 ng/ml) for 24 hours. (B) Immunofluorescence staining of TFE3-HA (green) and Western blot of stably expressed WT TFE3 (WT) or mTOR site-mutated TFE3 (S320A) RAW 264.7 cells. LPS (100 ng/ml, 24 hours). Scale bar: 10 μm. p-S6, phospho-S6 ribosomal protein (Ser240/244). (C) Relative mRNA expression in WT, FLCN KO, and DKO BMDMs. **P < 0.01 vs. WT. (D) Relative mRNA expression in the WT BMDMs exposed to vehicle, CpG, or LPS for 24 hours. *P < 0.05, **P < 0.01 vs. vehicle. (C and D) Values are represented as mean ± SEM from 3 independent experiments and were analyzed by 1-way ANOVA followed by t test (Bonferroni correction). (E) BMDMs transfected with a lentiviral CRISPR-Cas9 FLCN KO (FLCN KO) or nontarget control (NTC) on day 1 after isolation and then transfected with RagD siRNA or siControl on day 7. Western blot was performed on day 9 after isolation. (F) Proposed models of FLCN-mTOR-TFE3 axis in myeloid cells.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts